UBS Downgrades Galderma to Neutral as Aesthetics Market Faces Headwinds: What Investors Need to Know

In a notable shift within the healthcare investment landscape, UBS has adjusted its stance on Galderma Group AG (SIX: GALD), moving from a "buy" to a "neutral" rating. This change is primarily a response to growing apprehensions surrounding the company's valuation and a perceived softening in the aesthetics market segment.

The latest analysis from UBS revealed that, while Galderma's shares performed admirably in recent times, the firm is now wary about the limited potential for further upside. As a result, they have decreased their 12-month price target from CHF128 to CHF120, largely attributing this adjustment to fluctuations in currency exchange rates.

The findings from UBS's recent U.S. Aesthetics Survey, which encompassed responses from 61 practitioners, unveiled a two-sided narrative. There is continued strength in neuromodulator products, anticipated to grow by 7.1% over the coming six months-though this mirrors a slight dip from earlier projections of 7.7%. In stark contrast, the landscape for fillers looks rather bleak, with expectations now indicating a contraction of 0.5%, a far cry from the previously anticipated 6.2% growth. Meanwhile, growth in biostimulators has also seen a decline, dropping to a forecast of 3.6% from 6.9%.

With promotional activities on the rise-25% of survey participants noted increased discounting efforts-the implications for Galderma's upcoming financial reports are significant. Investors should expect the second quarter results to reflect slowing neuromodulator growth and only a partial recovery in filler sales. In the first quarter of 2025, Galderma's injectable aesthetics revenue rose by 9.9% on a constant exchange rate basis, buoyed by a notable 21.4% increase in neuromodulators. However, both fillers and biostimulators faced declines of 2.3%.

Despite early successes for Galderma's new product, Nemluvio, UBS has kept its peak sales forecasts at a modest $3 billion, projecting a sequential prescription growth of over 110% in the second quarter. However, the forecast is tempered by a conservative model anticipating only a 70% increase in sales, given the downward trend in units per prescription and rising rebate pressure, particularly in the context of atopic dermatitis.

On the valuation front, concerns were explicitly highlighted as Galderma currently trades at a striking 25.6x EV/EBITDA for the year 2026, and 20.6x when excluding Nemluvio. These figures represent significant premiums-73% and 36% respectively-when compared to local competitors like Straumann and Alcon (NYSE: ALC). UBS adopts a sum-of-the-parts valuation approach, placing the core business at a multiple of 20x 2026E EV/EBITDA while treating Nemluvio as a standalone asset.

Looking ahead, Galderma is projected to generate revenues of $4.91 billion in 2025, which is expected to rise to $5.66 billion in 2026. UBS forecasts a core EBITDA of $1.1 billion for 2025, representing a margin of 22.6%, alongside net earnings expected at $615 million. Notably, earnings per share (EPS) are anticipated to reach $2.59 in 2025 and increase to $3.88 by 2026. Furthermore, net debt is predicted to decline from $2.31 billion in 2024 to $1.99 billion in 2025.

For traders keeping a close eye on the stock market, these developments surrounding Galderma present a cautious yet important narrative. As valuation specifics and market dynamics play a critical role in shaping investment strategies, prudent decision-making will be essential for navigating these shifting tides in the aesthetics sector.